Federal contract award
75A50123C00066
CYTOVALE: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO EVALUATE THE IMPACT OF THE INTELLISEP TEST ON CLINICAL DECISION-MAKING AND ITS POTENTIAL TO AID IN IMPROVING SEPSIS RISK STRATIFICATION AND RESOURCE UTILIZATION. THE CONTRACT WILL SUPPORT THE SQU
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $599.6K |
| Current contract value | $599.6K |
| Potential contract value / ceiling | $599.6K |
| Start date | Sep 19, 2023 |
| Current end date | May 30, 2025 |
| Potential end date | May 30, 2025 |
| Latest award activity | May 7, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 7, 2025 | P00003 | $0 | CYTOVALE: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO EVALUATE THE IMPACT OF THE INTELLISEP TEST ON CLINICAL DECISION-MAKING AND ITS POTENTIAL TO AID IN IMPROVING SEPSIS RISK STRATIFICATION AND RESOURCE UTILIZATION. THE CONTRACT WILL SUPPORT THE SQU |
| Oct 20, 2024 | P00002 | $0 | CYTOVALE: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO EVALUATE THE IMPACT OF THE INTELLISEP TEST ON CLINICAL DECISION-MAKING AND ITS POTENTIAL TO AID IN IMPROVING SEPSIS RISK STRATIFICATION AND RESOURCE UTILIZATION. THE CONTRACT WILL SUPPORT THE SQU |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.